Association of MMP-3 5A/6A gene polymorphism with susceptibility to carotid atherosclerosis. 2008

Tamara Djurić, and Maja Zivković, and Djordje Radak, and Djole Jekić, and Sandra Radak, and Ljiljana Stojković, and Ranko Raicević, and Aleksandra Stanković, and Dragan Alavantić
VINCA Institute of Nuclear Sciences, Laboratory for Radiobiology and Molecular Genetics, P.O. Box 522, 11001 Belgrade, Serbia. tamariska@vin.bg.ac.yu

OBJECTIVE Stromelysin-1 (MMP-3) as a key member of metalloproteinase family could have an important role in atherogenesis. The 5A/6A polymorphism in the promoter of MMP-3 gene affects the level of MMP-3 gene expression. We assessed whether the MMP-3 promoter low- and high-activity genotypes are related to susceptibility for carotid atherosclerosis (CA) in Serbian population. METHODS The study group of case-control design consisted of 515 participants. The 265 patients with ultrasonographic evidence of carotid plaque presence were recruited for the study. The 5A/6A polymorphism was typed by RFLP-PCR. RESULTS There was significantly higher prevalence of genotypes containing 6A allele in the patients with CA compared to controls (p<0.05). The model of inheritance with the dominant effect of 6A allele gave elevated and significant OR for carotid atherosclerosis (adjusted OR 2.35, CI=1.0-5.5, p=0.048). CONCLUSIONS Subjects carrying genotypes with 6A allele had significantly higher susceptibility to carotid atherosclerosis.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002340 Carotid Artery Diseases Pathological conditions involving the CAROTID ARTERIES, including the common, internal, and external carotid arteries. ATHEROSCLEROSIS and TRAUMA are relatively frequent causes of carotid artery pathology. Carotid Atherosclerosis,Common Carotid Artery Disease,Internal Carotid Artery Disease,Arterial Diseases, Carotid,Arterial Diseases, Common Carotid,Arterial Diseases, External Carotid,Arterial Diseases, Internal Carotid,Atherosclerotic Disease, Carotid,Carotid Artery Disorders,Carotid Atherosclerotic Disease,Common Carotid Artery Diseases,External Carotid Artery Diseases,Internal Carotid Artery Diseases,Arterial Disease, Carotid,Artery Disease, Carotid,Artery Diseases, Carotid,Artery Disorder, Carotid,Artery Disorders, Carotid,Atherosclerotic Diseases, Carotid,Carotid Arterial Disease,Carotid Arterial Diseases,Carotid Artery Disease,Carotid Artery Disorder,Carotid Atheroscleroses,Carotid Atherosclerotic Diseases,Disorders, Carotid Artery
D005260 Female Females
D005787 Gene Frequency The proportion of one particular in the total of all ALLELES for one genetic locus in a breeding POPULATION. Allele Frequency,Genetic Equilibrium,Equilibrium, Genetic,Allele Frequencies,Frequencies, Allele,Frequencies, Gene,Frequency, Allele,Frequency, Gene,Gene Frequencies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016017 Odds Ratio The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases. Cross-Product Ratio,Risk Ratio,Relative Odds,Cross Product Ratio,Cross-Product Ratios,Odds Ratios,Odds, Relative,Ratio, Cross-Product,Ratio, Risk,Ratios, Cross-Product,Ratios, Risk,Risk Ratios
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D019278 Matrix Metalloproteinase 3 An extracellular endopeptidase of vertebrate tissues similar to MATRIX METALLOPROTEINASE 1. It digests PROTEOGLYCAN; FIBRONECTIN; COLLAGEN types III, IV, V, and IX, and activates procollagenase. (Enzyme Nomenclature, 1992) Stromelysin 1,Transin,MMP-3 Metalloproteinase,MMP3 Metalloproteinase,Stromelysin,MMP 3 Metalloproteinase,Metalloproteinase 3, Matrix,Metalloproteinase, MMP-3,Metalloproteinase, MMP3

Related Publications

Tamara Djurić, and Maja Zivković, and Djordje Radak, and Djole Jekić, and Sandra Radak, and Ljiljana Stojković, and Ranko Raicević, and Aleksandra Stanković, and Dragan Alavantić
February 2013, Rheumatology international,
Tamara Djurić, and Maja Zivković, and Djordje Radak, and Djole Jekić, and Sandra Radak, and Ljiljana Stojković, and Ranko Raicević, and Aleksandra Stanković, and Dragan Alavantić
September 2007, Annals of the New York Academy of Sciences,
Tamara Djurić, and Maja Zivković, and Djordje Radak, and Djole Jekić, and Sandra Radak, and Ljiljana Stojković, and Ranko Raicević, and Aleksandra Stanković, and Dragan Alavantić
December 2008, Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics,
Tamara Djurić, and Maja Zivković, and Djordje Radak, and Djole Jekić, and Sandra Radak, and Ljiljana Stojković, and Ranko Raicević, and Aleksandra Stanković, and Dragan Alavantić
June 2012, The Journal of surgical research,
Tamara Djurić, and Maja Zivković, and Djordje Radak, and Djole Jekić, and Sandra Radak, and Ljiljana Stojković, and Ranko Raicević, and Aleksandra Stanković, and Dragan Alavantić
March 2005, Journal of hypertension,
Tamara Djurić, and Maja Zivković, and Djordje Radak, and Djole Jekić, and Sandra Radak, and Ljiljana Stojković, and Ranko Raicević, and Aleksandra Stanković, and Dragan Alavantić
July 2023, Future oncology (London, England),
Tamara Djurić, and Maja Zivković, and Djordje Radak, and Djole Jekić, and Sandra Radak, and Ljiljana Stojković, and Ranko Raicević, and Aleksandra Stanković, and Dragan Alavantić
June 2006, Arteriosclerosis, thrombosis, and vascular biology,
Tamara Djurić, and Maja Zivković, and Djordje Radak, and Djole Jekić, and Sandra Radak, and Ljiljana Stojković, and Ranko Raicević, and Aleksandra Stanković, and Dragan Alavantić
April 2010, Indian journal of clinical biochemistry : IJCB,
Tamara Djurić, and Maja Zivković, and Djordje Radak, and Djole Jekić, and Sandra Radak, and Ljiljana Stojković, and Ranko Raicević, and Aleksandra Stanković, and Dragan Alavantić
November 2017, Brain research,
Tamara Djurić, and Maja Zivković, and Djordje Radak, and Djole Jekić, and Sandra Radak, and Ljiljana Stojković, and Ranko Raicević, and Aleksandra Stanković, and Dragan Alavantić
August 2012, Genetic testing and molecular biomarkers,
Copied contents to your clipboard!